MENU
+Compare
PDSB
Stock ticker: NASDAQ
AS OF
Jan 15, 10:37 AM (EDT)
Price
$1.46
Change
+$0.07 (+5.04%)
Capitalization
52M

PDSB PDS Biotechnology Corp Forecast, Technical & Fundamental Analysis

a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers

Industry Biotechnology
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for PDSB with price predictions
Jan 08, 2025

PDSB's Indicator enters downward trend

The Aroon Indicator for PDSB entered a downward trend on January 08, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 263 similar instances where the Aroon Indicator formed such a pattern. In of the 263 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PDSB as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PDSB's RSI Oscillator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 61 cases where PDSB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PDSB just turned positive on December 26, 2024. Looking at past instances where PDSB's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where PDSB advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .

PDSB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.364) is normal, around the industry mean (15.212). P/E Ratio (0.000) is within average values for comparable stocks, (87.972). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.839). PDSB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (258.672).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PDSB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

PDSB is expected to report earnings to rise 6.31% to -30 cents per share on March 27

PDS Biotechnology Corp PDSB Stock Earnings Reports
Q4'24
Est.
$-0.31
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.10
Q1'24
Beat
by $0.07
Q4'23
Beat
by $0.09
The last earnings report on November 14 showed earnings per share of -28 cents, beating the estimate of -30 cents. With 2.56K shares outstanding, the current market capitalization sits at 52.00M.
A.I. Advisor
published General Information

General Information

a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
303A College Road
Phone
+1 800 208-3343
Employees
25
Web
https://www.pdsbiotech.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ISDR8.970.20
+2.28%
Issuer Direct Corp
AGI19.550.39
+2.04%
Alamos Gold
COIN255.374.17
+1.66%
Coinbase Global
MGNI15.640.11
+0.71%
Magnite
TRVI3.93-0.06
-1.50%
Trevi Therapeutics

PDSB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with RXRX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
-2.11%
RXRX - PDSB
46%
Loosely correlated
-6.23%
AXON - PDSB
43%
Loosely correlated
+1.96%
PRME - PDSB
42%
Loosely correlated
-2.53%
BPMC - PDSB
42%
Loosely correlated
-0.77%
AVXL - PDSB
41%
Loosely correlated
-0.76%
More